Search

Search Results
Results 4451 - 4460 of 4465 for multiple sclerosis
  • Drug - 17 Sep 2020
    Consumer Medicine Information (CMI) about Dantrium Capsules (Dantrolene sodium hemiheptahydrate) intended for persons living in Australia.
  • White Paper - 28 Jan 2020
    This article discusses gamma Synuclein aggregation in neurodegenerative diseases.
  • White Paper - 14 Aug 2019
    This article describes a case study in which NMR was used in a metabolic analysis of Guillain Barre syndrome to identify biomarkers for the condition.
  • White Paper - 10 Jun 2019
    Bruker’s MRI instruments provide researchers with the reliable preclinical MRI quantification.
  • White Paper - 6 Jun 2019
    Metabotropic glutamate receptors are exciting therapeutic targets due to their involvement in cardiovascular and neurological diseases, and their widespread expression.
  • Drug - 9 Apr 2019
    Consumer Medicine Information (CMI) about Hexaxim (Diphtheria, tetanus, pertussis , hepatitis B , poliomyelitis and Haemophilus influenzae type b conjugate vaccine) intended for...
  • Health - 27 Feb 2019
    Rickets has been around for centuries, but its roots as a symptom of vitamin D deficiency began only in the 17th century, when Francis Glisson published his findings on the disease and proposed that...
  • News - 25 Jul 2012
    Elan Corporation, plc today reported its second quarter and first half 2012 financial results.
  • Drug - 16 May 2024
    Consumer Medicine Information (CMI) about Abrilada intended for persons living in Australia.
  • White Paper - 28 Oct 2019
    Reviewing the ligands mostly used as experimental tools for cannabinoid receptors can give a wider understanding of endocannabinoid systems.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.